Webinar on Infex's Phase II lead respiratory drug, RESP-X
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with…
Infex to present webinar on lead Phase II respiratory drug RESP-X
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…
Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
Listen to the podcast here Infex CEO Peter Jackson discusses the state of…
Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Alderley Park, Cheshire U.K. Infex Therapeutics, a leading anti-infectives…
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Antimicrobial discovery and drug development - RSC Podcast
How do we develop drugs like antibiotics? How long does it take for such a drug…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…